Related Experiment Videos
Mutagenicity of cytostatic drugs in a bacterial system. I. Ames test
1Research Institute of Pharmacy and Biochemistry Co. (VUFB), Pardubice-Rosice, Czech Republic.
Abstract:
A set of nine cytostatic drugs were tested in the standard plate incorporation method of Ames reversion test using four Salmonella typhimurium his strains. Six of them were classical and commonly used cytostatics, three (cloturin, butocin and oracin) are at different stages of development. The results showed 6-mercaptopurine, cloturin, adriamycin, mitoxantron, cyclophosphamide and lomustine to be mutagenic; butocin, oracin and tris(2-chloroethyl)amine were negative in this test.
Insights
Six common and developmental cytostatic drugs showed mutagenic potential in the Ames test, indicating a risk. However, three other cytostatics were found to be non-mutagenic in this bacterial assay.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Cytostatic drugs are widely used in cancer therapy.
- Assessing the mutagenicity of cytostatics is crucial for patient safety and drug development.
- The Ames test is a standard method for evaluating bacterial mutagenicity.
Purpose of the Study:
- To evaluate the mutagenic potential of nine cytostatic drugs.
- To assess both established and developmental cytostatics using the Ames test.
Main Methods:
- The standard plate incorporation method of the Ames reversion test was employed.
- Four Salmonella typhimurium his strains were used for the assays.
- Nine cytostatic drugs, including classical and developmental agents, were tested.
Main Results:
- Six cytostatic drugs demonstrated mutagenic activity: 6-mercaptopurine, cloturin, adriamycin, mitoxantron, cyclophosphamide, and lomustine.
- Three cytostatic drugs were found to be non-mutagenic: butocin, oracin, and tris(2-chloroethyl)amine.
- The results highlight differential mutagenic profiles among cytostatic agents.
Conclusions:
- Certain cytostatic drugs possess mutagenic properties, necessitating careful consideration in clinical use.
- Developmental cytostatics cloturin, butocin, and oracin show varied mutagenic outcomes.
- The Ames test provides valuable data for the safety assessment of cytostatic drugs.